Cargando…
Research progress on dendritic cell vaccines in cancer immunotherapy
Dendritic cell (DC) vaccines induce specific immune responses that can selectively eliminate target cells. In recent years, many studies have been conducted to explore DC vaccination in the treatment of hematological malignancies, including acute myeloid leukemia and myelodysplastic syndromes, as we...
Autores principales: | Yu, Jifeng, Sun, Hao, Cao, Weijie, Song, Yongping, Jiang, Zhongxing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784280/ https://www.ncbi.nlm.nih.gov/pubmed/35074008 http://dx.doi.org/10.1186/s40164-022-00257-2 |
Ejemplares similares
-
Targeting CD47 for cancer immunotherapy
por: Jiang, Zhongxing, et al.
Publicado: (2021) -
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
por: Cao, Weijie, et al.
Publicado: (2022) -
Applications of gut microbiota in patients with hematopoietic stem-cell transplantation
por: Yu, Jifeng, et al.
Publicado: (2020) -
Recent Progress in Dendritic Cell-Based Cancer Immunotherapy
por: Matsuo, Kazuhiko, et al.
Publicado: (2021) -
Advances in targeted therapy for acute myeloid leukemia
por: Yu, Jifeng, et al.
Publicado: (2020)